Affimed

Affimed EBITDA per Employee

Delisted

The EBITDA per Employee of Affimed (AFMD) as of Nov 19, 2026 is -824,625.00 EUR. In the previous year, EBITDA per Employee was -667,812.50 EUR — a change of 23.48% (lower).

EBITDA per Employee

-824,625.00EUR

YoY

23.48%

Last updated:

EBITDA per Employee of Affimed is 2023 -824,625.00 EUR. EBITDA per Employee of Affimed was 2022 -667,812.50 EUR. It decreases by 23.48% lower compared to the previous year.

The Affimed EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2016
-243,492.17 EUR
Jan 1, 2017
-213,130.47 EUR
Jan 1, 2018
-149,882.81 EUR
Jan 1, 2019
-247,273.44 EUR
Jan 1, 2020
-269,014.36 EUR
Jan 1, 2021
-491,976.56 EUR
Jan 1, 2022
-667,812.50 EUR
Jan 1, 2023
-824,625.00 EUR
The Affimed EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-824,625.00EUR+23.48%
-667,812.50EUR+35.74%
-491,976.56EUR+82.88%
-269,014.36EUR+8.79%
-247,273.44EUR+64.98%
-149,882.81EUR-29.68%
-213,130.47EUR-12.47%
-243,492.17EUR+48.17%
-164,335.94EUR+171.42%
-60,546.88EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Affimed Stock analysis

What does Affimed do? Affimed NV develops targeted cancer immunotherapies focused on immuno-oncology, leveraging the immune system to combat tumor cells. The company's product pipeline includes AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma, AFM13 combined with adoptive NK cells or anti-PD-1, and AFM24 for advanced EGFR-expressing solid tumors. Affimed is conducting a registration-directed study for AFM13 and a Phase 1/2a study for AFM24, alongside preclinical candidates like AMF26 for multiple myeloma and AMF28/AMF32 for multiple tumor targets. The firm collaborates with Genentech to develop and commercialize certain product candidates for multiple cancers. Affimed generates revenue primarily through collaboration agreements, such as the partnership with Genentech, which covers development and commercialization of specific therapies. The company's primary customers are pharmaceutical and biotechnology firms seeking to expand their oncology portfolios, particularly those interested in immuno-oncology approaches. Affimed's target segments include patients with relapsed/refractory peripheral T-cell Lymphoma, advanced EGFR-expressing solid tumors, and multiple myeloma, as well as broader oncology markets for its preclinical candidates. The company's revenue streams are tied to milestone payments and potential royalties from partnered products, with Genentech being a key collaborator. Affimed's focus on immuno-oncology positions it to attract partnerships with major pharmaceutical players looking to enhance their cancer therapy offerings. Its clinical-stage products, such as AFM13 and AFM24, are in advanced development phases, making them attractive for strategic alliances that drive commercialization and revenue generation. Affimed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Affimed stock

EBITDA per Employee of Affimed is -824,625.00 EUR in 2023.

EBITDA per Employee of Affimed changed from -667,812.50 EUR to -824,625.00 EUR, representing a 23.48% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Affimed since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Affimed historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Affimed

All Key Metrics — Affimed